Under what circumstances is it necessary to take carpizetin/Tunicote drugs?

Capivasertib is an oral small molecule inhibitor of AKT kinase, suitable for patients with locally advanced or metastatic breast cancer on a specific genetic background. Its core mechanism of action is to inhibit the PI3K/AKT signaling pathway, thereby blocking tumor cell proliferation and promoting apoptosis. Clinically, capizetin is usually used in combination with fulvestrant for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer, especially those with PIK3CA, AKT1 or PTEN gene changes.

The drug is mainly used for two categories of patients: one is patients with metastatic breast cancer who have received at least one endocrine-based treatment regimen but experienced disease progression; the other is patients who have relapsed within 12 months after completing adjuvant therapy. For these patients, traditional endocrine therapy has limited effect, while AKT pathway inhibitors can re-enhance the sensitivity of tumor cells to endocrine drugs and delay the progression of the disease. Before using carpisetin, it is usually necessary to confirm the PIK3CA, AKT1 or PTEN gene status through genetic testing to ensure drug targeting and effectiveness.

During the course of taking, the doctor will develop an individualized dosage plan based on the patient's body surface area, kidney and liver function, and previous treatment history. Common adverse reactions include diarrhea, rash, fatigue, and blood sugar fluctuations, but they are generally controllable and can be managed with supportive care and dose adjustment. Patients need regular follow-up and laboratory examinations during use to monitor the efficacy and safety of the drug.

In short, the application of carpisetig emphasizes the concept of precision treatment and is only suitable for use in patients withHR+, HER2- breast cancer and related genetic changes. Its combination with fulvestrant can effectively delay disease progression and provide new treatment options for patients with endocrine resistance or relapse.

Reference materials:https://www.drugs.com/mtm/capivasertib.html